Evaluation and Management of Unresectable Hepatocellular Carcinoma: Multidisciplinary Indian Consensus Statements from a Delphi Panel
Open Access
- 22 July 2024
- journal article
- review article
- Published by Scientific Scholar in South Asian Journal of Cancer
- Vol. 14 (02) , 123-134
Abstract
India, like many parts of Asia, likely faces a high burden of hepatocellular carcinoma (HCC), though large-scale data on etiology, presentation, and outcomes are lacking. There appears to be a predominance of unresectable, advanced-stage HCC at presentation in India with variable level of expertise in India to manage these scenarios. This publication summarizes the latest evidence with cognizance of the unique challenges faced in India by treating clinicians. A multidisciplinary panel of medical oncologists, gastroenterologists, hepatologists, interventional radiologists, and hepatobiliary surgical oncologists held a meeting in June 2022 and reviewed the evidence available for management of HCC. The meeting concentrated on the recognition and management of HCC not amenable to surgical approaches in the Indian context. A literature review of these aspects of management was conducted and consensus statements with level of evidence and grades of recommendation were prepared by individual specialists in each field. Statements were evaluated by the modified Delphi method. The panel comprising 22 experts formulated 40 consensus statements with regard to defining unresectable HCC, optimization of underlying conditions prior to management, rationale use of various liver-directed therapies (LDTs) in unresectable HCC, and systemic therapeutic options in this group of patients. Our consensus statements offer practical, yet evidence-based management guidelines for treating unresectable HCC in the Indian context. There is an emphasis on the crucial need for combining available approaches for LDT, even if less well studied though possibly effective, with standard systemic therapy.Keywords
This publication has 94 references indexed in Scilit:
- TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysisCancer Medicine, 2022
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With SorafenibJAMA Oncology, 2020
- A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacyCancer, 2019
- Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular InvasionJAMA Oncology, 2018
- Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide surveyHepatology, 2017
- Albumin–bilirubin versus Child–Pugh score as a predictor of outcome after liver resection for hepatocellular carcinomaBritish Journal of Surgery, 2016
- Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta‐analysisHepatology, 2015
- Outcomes of hepatic resection for huge hepatocellular carcinoma (≥10 cm in diameter)Journal of Surgical Oncology, 2011
- Selection Criteria for Hepatectomy in Patients with Hepatocellular Carcinoma Classified as Child‐Pugh Class BWorld Journal of Surgery, 2010
- Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinomaCancer, 2005